50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
NASDAQ:LNTH

Lantheus - LNTH Stock Forecast, Price & News

$66.60
-1.76 (-2.57%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$66.10
$69.03
50-Day Range
$66.60
$86.60
52-Week Range
$22.20
$87.47
Volume
1.20 million shs
Average Volume
1.10 million shs
Market Capitalization
$4.58 billion
P/E Ratio
154.88
Dividend Yield
N/A
Price Target
$98.33

Lantheus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
47.6% Upside
$98.33 Price Target
Short Interest
Healthy
4.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
0.31mentions of Lantheus in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$4.23 M Sold Last Quarter
Proj. Earnings Growth
13.98%
From $3.29 to $3.75 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

184th out of 1,069 stocks

Diagnostic Substances Industry

4th out of 16 stocks

LNTH stock logo

About Lantheus (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Stock News Headlines

Are Medical Stocks Lagging Lantheus (LNTH) This Year?
3 Small-Cap Stocks That Could 10X by 2027 - InvestorPlace
See More Headlines
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Company Calendar

Last Earnings
8/04/2022
Today
9/26/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LNTH
Employees
612
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$98.33
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$91.00
Forecasted Upside/Downside
+47.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-71,280,000.00
Pretax Margin
8.90%

Debt

Sales & Book Value

Annual Sales
$425.21 million
Cash Flow
$1.25 per share
Book Value
$6.86 per share

Miscellaneous

Free Float
67,642,000
Market Cap
$4.58 billion
Optionable
Optionable
Beta
0.77

Key Executives

  • Ms. Mary Anne HeinoMs. Mary Anne Heino (Age 62)
    CEO, Pres & Director
    Comp: $2.15M
  • Mr. Robert J. Marshall Jr.Mr. Robert J. Marshall Jr. (Age 54)
    CFA, CFO & Treasurer
    Comp: $905.94k
  • Mr. Paul M. BlanchfieldMr. Paul M. Blanchfield (Age 41)
    Chief Operating Officer
    Comp: $734.54k
  • Mr. Daniel M. NiedzwieckiMr. Daniel M. Niedzwiecki (Age 45)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $627.1k
  • Mr. Etienne MontagutMr. Etienne Montagut (Age 47)
    Chief Bus. Officer
    Comp: $607.99k
  • Ms. Andrea SabensMs. Andrea Sabens (Age 43)
    Principal Accounting Officer
  • Mr. Mark Richard Kinarney
    Sr. Director of Investor Relations
  • Ms. Linda S. Lennox (Age 57)
    VP of Corp. Communications & Chief of Staff
  • Melissa Downs
    Director of Corp. Communications
  • Ms. Ying Yao (Age 48)
    Chief HR Officer













LNTH Stock - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings
or view top-rated stocks.

What is Lantheus' stock price forecast for 2022?

3 brokerages have issued 1 year price objectives for Lantheus' stock. Their LNTH share price forecasts range from $91.00 to $110.00. On average, they anticipate the company's stock price to reach $98.33 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price.
View analysts price targets for LNTH
or view top-rated stocks among Wall Street analysts.

How have LNTH shares performed in 2022?

Lantheus' stock was trading at $28.89 on January 1st, 2022. Since then, LNTH shares have increased by 133.3% and is now trading at $67.39.
View the best growth stocks for 2022 here
.

When is Lantheus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our LNTH earnings forecast
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, August, 4th. The medical equipment provider reported $0.81 EPS for the quarter, beating the consensus estimate of $0.64 by $0.17. The medical equipment provider had revenue of $223.80 million for the quarter, compared to the consensus estimate of $204.51 million. Lantheus had a net margin of 4.88% and a trailing twelve-month return on equity of 28.88%. The firm's revenue for the quarter was up 121.4% on a year-over-year basis. During the same period last year, the business posted $0.11 earnings per share.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its third quarter 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share (EPS) guidance of $0.80-$0.85 for the period, compared to the consensus estimate of $0.69. The company issued revenue guidance of $220.00 million-$230.00 million, compared to the consensus revenue estimate of $204.57 million.

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?
When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (3.48%), Price T Rowe Associates Inc. MD (3.37%), Artisan Partners Limited Partnership (1.81%), Thrivent Financial for Lutherans (1.56%), Driehaus Capital Management LLC (1.27%) and Northern Trust Corp (1.23%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends
.

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $67.39.

How much money does Lantheus make?

Lantheus (NASDAQ:LNTH) has a market capitalization of $4.63 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71,280,000.00 in net income (profit) each year or $0.43 on an earnings per share basis.

How many employees does Lantheus have?

The company employs 612 workers across the globe.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860.

This page (NASDAQ:LNTH) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.